NCT06745583 2026-04-09
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Phase 2 Recruiting
Clinical Trials
20 trialsNCT05522387 2026-02-27
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Inmune Bio, Inc.
Phase 2 Terminated
NCT06125951 2026-02-18
XanaMIA
Actinogen Medical
Phase 2/3 Active not recruiting
NCT05637801 2026-02-05
Hope
Cognito Therapeutics, Inc.
Phase NA Active not recruiting
NCT05425550 2025-09-22
PRO2
Palleos Healthcare GmbH
Phase NA Terminated
NCT04971733 2025-06-10
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
Eisai Inc.
Phase 1/2 Completed
NCT06644573 2025-05-28
PSHW
PROSOMNIA Sleep Health & Wellness
Phase 1 Not yet recruiting
NCT03089918 2025-04-27
A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain
Janssen Research & Development, LLC
Phase 1 Completed
NCT05328115 2025-01-31
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
Alzinova AB
Phase 1 Completed
NCT06245031 2024-05-07
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
Cognito Therapeutics, Inc.
Phase NA Enrolling by invitation
NCT05321498 2023-09-28
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
Inmune Bio, Inc.
Phase 2 Withdrawn
NCT03371420 2023-04-18
PET Imaging of Subjects Using 124I-PU-AD
Samus Therapeutics, Inc.
Phase EARLY_PHASE1 Terminated
NCT03556280 2021-08-24
Overture
Cognito Therapeutics, Inc.
Phase NA Active not recruiting
NCT03661034 2021-08-24
Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)
Cognito Therapeutics, Inc.
Phase NA Unknown
NCT02632786 2019-04-05
PRONTO
Prothena Biosciences Ltd.
Phase 2 Completed
NCT00348140 2017-09-05
REFLECT-3
GlaxoSmithKline
Phase 3 Completed
NCT02859207 2017-06-08
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
Eisai Inc.
Phase 1 Completed
NCT00428090 2017-05-19
Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
GlaxoSmithKline
Phase 3 Completed
NCT00411580 2013-03-29
Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)
Novartis
Phase 1 Completed
NCT00711204 2012-12-10
Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease
Eisai Inc.
Phase 4 Withdrawn